Cost-effectiveness of daratumumab in multiple myeloma treatment: A systematic review
Các tác giả
DOI: https://doi.org/10.59294/HIUJS2025029Từ khóa:
systematic review, cost-effectiveness, daratumumab, multiple myelomaTóm tắt
Introduction: The cost-effectiveness of daratumumab in multiple myeloma treatment is a considerable criterion in clinical practice with tight health budgets. This review aimed to evaluate the cost-effectiveness of daratumumab in the treatment of multiple myeloma. Methods: The systematic review method was conducted under the guidance of PRISMA, identifying through a literature search from 3 databases (Embase, PubMed, and Cochrane) with relevant keywords. Nine articles among 95 found articles, satisfying the inclusion criteria, were analyzed. All studies were conducted in the US and China between 2017 and 2021, assessing the cost-effectiveness of adding daratumumab to current regimens. Results: Most of the studies were from a payer perspective, with ICER of $30,893-$1,445,533/QALY. Daratumumab was found to be cost-effective in 2 studies and not cost-effective in comparison with regimens without daratumumab in 7 remaining studies. Conclusions: The systematic review evaluating the cost-effectiveness of daratumumab in multiple myeloma treatment recorded varied ICER results ranging from $30,893/QALY to $1,445,533/QALY with heterogeneous conclusions about cost-effectiveness, The US and China are the only setting countries. More similar studies in developing countries are required to fully evaluate the cost-effectiveness of daratumumab in the treatment of multiple myeloma.
Abstract
Introduction: The cost-effectiveness of daratumumab in multiple myeloma treatment is a considerable criterion in clinical practice with tight health budgets. This review aimed to evaluate the cost-effectiveness of daratumumab in the treatment of multiple myeloma. Methods: The systematic review method was conducted under the guidance of PRISMA, identifying through a literature search from 3 databases (Embase, PubMed, and Cochrane) with relevant keywords. Nine articles among 95 found articles, satisfying the inclusion criteria, were analyzed. All studies were conducted in the US and China between 2017 and 2021, assessing the cost-effectiveness of adding daratumumab to current regimens. Results: Most of the studies were from a payer perspective, with ICER of $30,893-$1,445,533/QALY. Daratumumab was found to be cost-effective in 2 studies and not cost-effective in comparison with regimens without daratumumab in 7 remaining studies. Conclusions: The systematic review evaluating the cost-effectiveness of daratumumab in multiple myeloma treatment recorded varied ICER results ranging from $30,893/QALY to $1,445,533/QALY with heterogeneous conclusions about cost-effectiveness, The US and China are the only setting countries. More similar studies in developing countries are required to fully evaluate the cost-effectiveness of daratumumab in the treatment of multiple myeloma.
Tài liệu tham khảo
[1] NCI Staff, "FDA Approves New Use for Daratumumab in Multiple Myeloma", 2016. Available: https://www.cancer.gov/news-events/cancer-currents-blog/2016/daratumumab-fda-myeloma-new. [Accessed: 17/10, 2021].
[2] THE WORLD BANK, "Consumer price index (2010 = 100)", International Monetary Fund, International Financial Statistics and data files., 2020. https://data.worldbank.org/, [Online]. Available: https://data.worldbank.org/indicator/FP.CPI.TOTL?end=2020&start=2016&fbclid=IwAR00mkcHRte9LH xogufarePfjbKIBUIzPJB-jHcsTET26jZyua4v2kiF4rE. [Accessed: 17/10, 2021].
[3] Husereau D. et al., "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force," Value Health. 16 (2), pp. 231-250, 2013.
DOI: https://doi.org/10.1016/j.jval.2013.02.002[4] Pelligra C. G. et al., "Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States," Clin Ther. 39 (10), pp. 1986-2005.e1985, 2017.
DOI: https://doi.org/10.1016/j.clinthera.2017.08.010[5] Zhang T. T. et al., "Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma," Clin Ther. 40 (7), pp. 1122-1139, 2018
DOI: https://doi.org/10.1016/j.clinthera.2018.05.012[6] Carlson J. J. et al., "Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States," J Manag Care Spec Pharm. 24 (1), pp. 29-38, 2018.
DOI: https://doi.org/10.18553/jmcp.2018.24.1.29[7] Gong C. L. et al., "Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis," Am J Hematol. 94 (3), pp. E68-e70, 2019.
DOI: https://doi.org/10.1002/ajh.25372[8] Zeng X. et al., "Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR," Clin Ther. 42 (2), pp. 251-262.e255, 2020.
DOI: https://doi.org/10.1016/j.clinthera.2019.12.007[9] Patel K. K. et al., "Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma," J Clin Oncol. 39 (10), pp. 1119-1128, 2021.
DOI: https://doi.org/10.1200/JCO.20.01849[10] Zeng X. et al., "Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma," Adv Ther. 38 (5), pp. 2379-2390, 2021
DOI: https://doi.org/10.1007/s12325-021-01699-6[11] Li S. et al., "First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis," Clinical Therapeutics, vol.43, no.7, pp. 1253-1264.e5, Jul 2021.
DOI: https://doi.org/10.1016/j.clinthera.2021.05.015[12] Cao Y. et al., "Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma," Front Pharmacol. 12, pp. 608685, 2021
DOI: https://doi.org/10.3389/fphar.2021.608685[13] Perry S. et al., "Cost Effectiveness of Novel Agents in the Treatment of Multiple Myeloma: A Systematic Review," Blood. 134 (Supplement_1), pp. 4738-4738, 2019.
DOI: https://doi.org/10.1182/blood-2019-125454[14] Chen Z. et al., "Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review," Expert Review of Pharmacoeconomics & Outcomes Research. 21 (5), pp. 923-941, 2021
DOI: https://doi.org/10.1080/14737167.2021.1913056
Tải xuống
Tải xuống: 15
Đã xuất bản
Cách trích dẫn
Số
Chuyên mục
